Emerging Real-World Evidence Suggests Differential Outcomes Between Abiraterone and Darolutamide in Hormone-Sensitive Prostate Cancer

/in /by

Agents such as abiraterone and darolutamide have demonstrated significant survival benefits in randomized clinical trials, yet direct comparative evidence between these therapies, particularly in the pre-chemotherapy setting, remains notably absent. A recent retrospective cohort analysis leveraging the TriNetX database attempts to address this gap by comparing real-world outcomes in patients treated with ADT plus either […]

Read more

Darolutamide Linked to Cognitive Benefit Over Enzalutamide in Prostate Cancer

/in , , , , /by

Darolutamide (Nubeqa) caused significantly less cognitive decline than enzalutamide (Xtandi) over 24 weeks in men with advanced prostate cancer, according to results from the phase 2 ARACOG trial, which are scheduled to be presented at the 2026 ASCO Annual Meeting. The findings represent the first randomized, prospective head-to-head comparison of the cognitive effects of two […]

Read more

CT‑Measured Muscle Quality Predicts Survival in Men with Non‑Metastatic Castration‑Resistant Prostate Cancer

/in /by

Researchers in Japan have found that muscle “quality,” not just size, is linked to how long men with non‑metastatic castration‑resistant prostate cancer (nmCRPC) live, even when they are treated with androgen receptor signaling inhibitors. The study analyzed 344 men using standard CT scans to measure muscle quantity and the amount of fat inside the muscle, […]

Read more

When Scans Stay Stable: How Progression‑Free Survival Reflects Survival in mCRPC

/in /by

At the 2026 American Urological Association (AUA) Annual Meeting, researchers showed that radiographic progression‑free survival (rPFS), the time from treatment start until scans show clear cancer progression or death, is a strong and meaningful reflection of overall survival in men with metastatic castration‑resistant prostate cancer (mCRPC). Using individual‑patient data from the large TALAPRO‑2 trial, they […]

Read more

Phase 3 PSMAddition Trial Reports Positive Outcomes for mHSPC

/in , , /by

Results from the PSMAddition trial were published in a phase 3 setting and showed several clear numbers worth noting. The trial compared standard double hormone-based treatment alone (ADT + ARPI) versus the same treatment plus a PSMA-targeted radioligand therapy (Pluvicto), in men with metastatic hormone-sensitive prostate cancer.The biggest headline was a 58% lower risk of […]

Read more

ARASEC Trial Validates Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

/in , , /by

The ARASEC trial, offers compelling evidence for darolutamide combined with androgen deprivation therapy as a treatment option for men with metastatic hormone-sensitive prostate cancer. This Phase 2 study tackled a challenging ethical dilemma in modern clinical trial design: how to evaluate a new treatment when randomizing patients to receive only standard ADT would be considered […]

Read more

Telmisartan: A Familiar Blood Pressure Pill with New Potential in Cancer Therapy

/in , /by

Telmisartan, a widely used blood pressure drug, has shown unexpected promise as a booster for cancer treatment. Preclinical research indicates that when telmisartan is combined with the PARP inhibitor olaparib, cancer cells accumulate more DNA damage and become more vulnerable to treatment, even if they do not carry the usual BRCA‑type DNA repair defects that […]

Read more

Targeted Alpha Therapy Plus PARP Blockade: AZD2265 plus AZD9574 for Advanced Prostate Cancer

/in , , , /by

There is a new flexible trial for men with metastatic prostate cancer that has stopped responding to hormone therapy. Phase 1/2 PROSPECTOR trial tests three options: a PSMA‑targeted radioactive drug (AZD2265), the same drug combined with a PARP1 inhibitor (AZD9574), and standard docetaxel chemotherapy. The first part of the trial finds safe dose levels and […]

Read more